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Primary strains of human immunodeficiency virus type 1 (HIV-1) are known to adapt to replication in cell lines in vitro by becoming
sensitive to soluble CD4 (sCD4) and neutralizing antibodies (NAb). T-cell lines favor isolation of variants that use CXCR4 as a co-receptor,
while primary isolates predominantly use CCR5. We have now studied how a primary R5 isolate, CC1/85, adapts to prolonged replication in
primary human peripheral blood mononuclear cells (PBMC). After 19 passages, a variant virus, CCcon.19, had increased sensitivity to both
sCD4 and NAb b12 that binds to a CD4-binding site (CD4BS)-associated epitope, but decreased sensitivity to anti-CD4 antibodies.
CCcon.19 retains the R5 phenotype, its resistance to other NAbs was unaltered, its sensitivity to various entry inhibitors was unchanged, and
its ability to replicate in macrophages was modestly increased. We define CCcon.19 as a primary T-cell adapted (PTCA) variant. Genetic
sequence analysis combined with mutagenesis studies on clonal, chimeric viruses derived from CC1/85 and the PTCA variant showed that
the most important changes were in the V1/V2 loop structure, one of them involving the loss of an N-linked glycosylation site. Monomeric
gp120 proteins expressed from CC1/85 and the PTCA variant did not differ in their affinities for sCD4, suggesting that the structural
consequences of the sequence changes were manifested at the level of the native, trimeric Env complex. Overall, the adaptation process
probably involves selection for variants with higher CD4 affinity and hence greater fusion efficiency, but this also involves the loss of some
resistance to neutralization by agents directed at or near to the CD4BS. The loss of neutralization resistance is of no relevance under in vitro
conditions, but NAbs would presumably be a counter-selection pressure against such adaptive changes in vivo, at least when the humoral
immune response is intact.
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Introduction to a new host because sexual transmission is such anHuman immunodeficiency virus type 1 (HIV-1) has
evolved multiple mechanisms to resist neutralization by
antibodies (Burton, 2002; Johnson and Desrosiers, 2002;
Moore and Ho, 1995; Moore et al., 1995; Parren et al.,
1999; Poignard et al., 2001). These devices are necessary
for the virus to persist long enough in vivo to be transmitted0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: jpm2003@med.cornell.edu (J.P. Moore).inefficient process, usually requiring many contacts over a
prolonged period (Shattock and Moore, 2003). The humoral
immune response to HIV-1 is vigorous; antibodies to the
viral envelope glycoproteins (Env) gp120 and gp41 are
generated at very high titers and persist throughout the
course of infection (Binley et al., 1997; Cheingsong-Popov
et al., 1991; Parren et al., 1999; Richman et al., 2003; Wei et
al., 2003). Unfortunately, most anti-Env antibodies are
unable to neutralize the virus because they fail to bind to
functional spikes on infectious virions or infected cells
(Herrera et al., 2003; Parren et al., 1999; Poignard et al.,
2003). And whenever neutralization does occur successful-
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variants (Arendrup et al., 1993; Moore et al., 1995; Parren
et al., 1999; Reitz et al., 1988; Richman et al., 2003; Wei et
al., 2003). These evasion and escape pathways are major
obstacles for the immune system in its fight with HIV-1, and
they also present serious problems for the design of vaccines
based on humoral immunity and of some drugs that prevent
HIV-1 entry (Moore and Doms, 2003; Moore and Steven-
son, 2000; Parren et al., 1999). For example, the clinical
development of soluble CD4 (sCD4) was derailed by the
insensitivity of primary isolates to this engineered molecule
(Ashkenazi et al., 1991; Daar et al., 1990; Moore and Sweet,
1993; Moore et al., 1992, 1993; Willey et al., 1994). The
sCD4 binding site on gp120 is similar, but not identical, to
those for neutralizing antibodies (NAb) directed against
epitopes proximal to the CD4-binding site (CD4BS)
(Olshevsky et al., 1990; Pantophlet et al., 2003; Thali et
al., 1992). Resistance to sCD4 may be merely a coincidental
consequence of HIV-1’s natural defense mechanisms against
NAbs to the CD4BS-associated epitopes (Moore and Ho,
1993, 1995).
Although HIV-1 is well equipped to resist the effect of
NAbs in vivo, it becomes neutralization-sensitive when
cultured in vitro (Clapham and McKnight, 2002; Moore
and Ho, 1995; Moore et al., 1992, 1993, 1995; Turner et al.,
1992; Wrin et al., 1995). This can be a rapid process, taking
only a few replication cycles. Moreover, when a neutrali-
zation-sensitive, in vitro-adapted, or engineered virus infects
a monkey, or accidentally, a human, then readaptation to the
neutralization-resistant phenotype occurs (Beaumont et al.,
2001; Cheng-Mayer et al., 1999; Etemad-Moghadam et al.,
2000; Si et al., 2001). Neutralization-sensitive viruses sim-
ply do not persist in vivo (Johnson et al., 2002, 2003).
Neutralization resistance seems, therefore, to be dispens-
able, but only if antibodies with actual or potential neutral-
izing activity are absent from the environment in which the
virus is replicating.
Does HIV-1 pay a price for its protection from NAbs? In
other words, is the virus’s rate of replication slowed by the
armor that it is, metaphorically, carrying? This has long been
hypothesized (Moore and Ho, 1995), but never satisfactorily
answered, because most in vitro adaptation experiments
have involved the passage of HIV-1 into a permanent cell
line to make a T-cell line-adapted (TCLA) strain. T-cell lines
almost invariably differ from primary CD4+ T cells in the
identity or quantity of the viral co-receptors that they
express (Berger et al., 1999; Clapham and McKnight,
2002). While most primary HIV-1 strains have the R5
phenotype, a minor X4 component is often present (Shan-
karappa et al., 1999). These viruses may be able to emerge
fully only when CCR5 is not available (Kinter et al., 1998).
Thus, most T-cell lines express the CXCR4 co-receptor, but
not CCR5, which allows the isolation of only X4 viruses.
Even if the cell line does express CCR5, it usually does so at
a level that differs from what is present on primary CD4+ T
cells, and the level of CCR5 expression is an adverseinfluence on the potency of entry inhibitors (Doms, 2000;
Lee et al., 1999; Moore and Doms, 2003; Platt et al., 2000;
Reeves et al., 2002). Like resistance to neutralizing anti-
bodies, co-receptor usage is determined by the structure of
the viral Env complex (Berger et al., 1999; Clapham and
McKnight, 2002; Poignard et al., 2001). An additional, but
interrelated variable is the amount of CD4 present on the
target cell, which can become limiting for entry when co-
receptor expression levels are below a certain threshold
(Platt et al., 1998). This factor may be particularly relevant
to the entry of X4 variants, as these viruses are more
sensitive than R5 strains to the cell surface CD4 concentra-
tion; indeed, X4 viruses are unable to infect cells expressing
very low levels of CD4 (Kozak et al., 1997; Tokunaga et al.,
2001). Moreover, HIV-1 uses different methods to attach to
different cell types before CD4 and co-receptor engagement,
and these attachment processes are also Env-dependent
(Mondor et al., 1998). For example, HIV-1 binds to heparin
sulfate proteoglycans on several cell lines via gp120, but
this is a minor attachment mechanism for primary CD4+ T
cells (Ibrahim et al., 1999; Mondor et al., 1998; Patel et al.,
1993; Spenlehauer et al., 2001). Consequently, it is hard to
discriminate between multiple, sometimes overlapping
influences when studying why a primary virus becomes
sensitive to NAbs upon passage in vitro. Is it the absence of
NAbs that allows the virus to discard its protective armor?
Or are other factors involved in adaptation to growth in cell
lines also relevant?
To address these questions, we have cultured an R5
primary HIV-1 isolate, CC1/85, for a prolonged period only
in primary, mitogen-stimulated human peripheral blood
mononuclear cells (PBMC), to minimize the variables
involved in vitro adaptation. We found that the adapted
virus, CCcon.19, eventually became more sensitive to sCD4
and the b12 NAb, although it retained its resistance to
several other monoclonal antibodies (MAbs) and entry
inhibitors. CCcon.19 was also less sensitive than CC1/85
to anti-CD4 MAbs. These phenotypic changes were associ-
ated with three amino acid substitutions in the V2 region of
gp120, one of which eliminated an N-linked glycan site. We
believe these findings are consistent with the concept that
changes in Env can increase the rate of receptor binding and
fusion, but may also cause an increase in neutralization
sensitivity. Sometimes this price is worth paying (in vitro),
sometimes not (in the face of an effective humoral immune
response, in vivo). In the end, HIV-1 strikes the appropriate
balance between attacking its receptors and defending itself
against the NAbs that try to prevent receptor binding.Results
Generation of a PBMC-adapted HIV-1 variant
We have previously described the generation of an
escape mutant, CC101.19, under the selection pressure of
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1 entry (Kuhmann et al., in press; Trkola et al., 2002).
The creation of this escape variant necessitated the
continuous passage of the R5 primary HIV-1 isolate
CC1/85 in PBMC in the presence of increasing AD101
concentrations. As a control, CC1/85 was passaged in
PBMC from the same donors, but in the absence of
AD101. Thus, by the time a virus emerged that was
essentially completely resistant to AD101, the control
culture contained a CC1/85 variant, CCcon.19, that had
been grown continuously in PBMC for 19 weeks (Fig. 1).
We reasoned that its extensive history of in vitro replica-
tion might have altered the phenotypic properties of CC1/
85, despite its maintenance only in primary cells. WeFig. 1. Generation of CCcon.19, a PBMC-adapted R5 HIV-1 variant. (A)
HIV-1 primary isolate CC1/85 was cultured in primary CD4+ T cells. The
extent of virus replication (p24 antigen production) at each passage is
shown. (B) HIV-1 isolates NL4-3 (X4), CC1/85 (R5), and CCcon.19 were
used to infect primary CD4+ T cells from donors expressing wild type CCR5
(filled bars) and donors homozygous for the CCR5-D32 mutation (open
bars). The amount of p24 antigen produced in the absence and presence of
100 nM AMD3100 is shown. The error bars represent the SEM of values
from three independent experiments.designate the CCcon.19 virus as a ‘‘primary T-cell adap-
ted’’ (PTCA) HIV-1 variant.
Co-receptor usage profile of PTCA variant CCcon.19
We first determined whether its 19-week passage in
PBMC had affected the co-receptor usage profile of CC1/
85 (Connor et al., 1997; Trkola et al., 2002). Neither
CC1/85 nor CCcon.19 could replicate in PBMC from two
different donors who were homozygous for the CCR5-
D32 allele and so lack CCR5 (Fig. 1B). Hence, both CC1/
85 and CCcon.19 absolutely require CCR5 for replication.
Furthermore, neither virus could replicate in GHOST-CD4
cells that expressed CXCR4, but both could do so in
GHOST-CD4-CCR5 cells (data not shown). The replica-
tion of both CC1/85 and CCcon.19 in PBMC were
completely inhibited by similar concentrations of the
CCR5 inhibitors SCH-C, MAb PA14, and RANTES
(Figs. 2A–C, Table 1), but both viruses were insensitive
to the CXCR4-specific inhibitor, AMD3100 (Fig. 1B,
Table 1). We conclude that the co-receptor usage profile
of CC1/85 was unaltered by its passage in PBMC, and
that CCcon.19 has retained the original R5 phenotype of
CC1/85. We could find no evidence that CCcon.19 can
use CXCR4 for entry.
PTCA variant CCcon.19 has acquired sCD4 sensitivity
Because passage of HIV-1 primary viruses in T-cell lines
has long been known to cause the acquisition of sCD4
sensitivity (Daar et al., 1990; Gomatos et al., 1990), we
determined whether the prolonged culture of CC1/85 in
PBMC had had a similar effect on its phenotype. Clearly,
CCcon.19 was much more sensitive than CC1/85 to sCD4;
in a PBMC-based replication assay, an approximately 100-
fold lower concentration of sCD4 was required to neutralize
CCcon.19 than CC1/85 (Fig. 3A, Table 1). CC101.19, a
CC1/85-derived virus that was passaged in PBMC from the
same donors in the presence of increasing concentrations of
AD101, remained as resistant as the input CC1/85 virus to
sCD4 (data not shown).
To see whether the decreased resistance of CCcon.19 to
sCD4 was specific for this agent, we also tested the broadly
neutralizing anti-gp120 MAb b12 to an epitope overlapping
the CD4BS. The b12 MAb neutralized CCcon.19 at an
approximately 10-fold lower concentration compared to
CC1/85 (Fig. 3B, Table 1). However, the neutralizing con-
centrations of the anti-gp120 MAbs 2G12 and 447-52D and
the anti-gp41 MAbs 2F5 and 4E10 were similar for CC1/85
and CCcon.19 (Figs. 3C–E, Table 1). CCcon.19 had also not
acquired sensitivity to MAbs 205-42-15, 205-43-1, and 205-
46-9 that recognize conserved CD4BS-associated epitopes
but which are able to neutralize only TCLA viruses and not
primary isolates (Table 1) (Fouts et al., 1998). Moreover,
CC1/85 and CCcon.19 were inhibited by similar concen-
trations of the gp41-peptide-based fusion inhibitor T-1249
Fig. 2. The PTCA virus CCcon.19 is sensitive to CCR5 inhibitors. Isolates
CC1/85 (filled circles) and CCcon.19 (open circles) were tested for their
sensitivity in primary CD4+ T cells to (A) SCH-C, (B) RANTES, and (C)
MAb PA14. The extent of virus replication is presented as a percentage of
p24 antigen production in the control culture (defined as 100%). The error
bars represent the SEM of values from three independent experiments.
Table 1
Inhibition of HIV-1 isolates CC1/85 and CCcon.19 by a panel of inhibitors
in primary CD4+ T cells
Inhibitor (target) IC50 for CC1/85
(Ag/ml)a
IC50 for CCcon.19
(Ag/ml)a
sCD4 (gp120 CD4bs) >50 0.7
b12 (gp120 CD4bs) 6.0 0.3
2F5 (gp41) >50 35.0
4E10 (gp41) 44.4 >50
2G12 (gp120) 1.8 4.2
447-52D (gp120 V3) >50 >50
205-46-9 (gp120 CD4bs) >50 >50
205-42-15 (gp120 CD4bs) >50 >50
205-43-1 (gp120 CD4bs) >50 >50
T1249 (gp41) 0.1 0.1
AD101 (CCR5) <0.3b <0.3b
SCH-C (CCR5) 3.7b 6.5b
AMD3100 (CXCR4) >100b >100b
PA14 (CCR5) 0.2 0.1
RANTES (CCR5) 0.05 0.04
2D7 (CCR5) 0.5 0.3
PA2 (CD4 D1) 0.6 >25
L222 (CD4 D1 CDR2) 0.4 2.8
Q4120 (CD4 D1 CDR1/2) 0.2 2.1
13B.8.2. (CD4 D1 CDR3) 0.2 5.0
a IC50 values for sCD4 inhibition curves were interpolated by fitting the
data to a sigmoidal curve.
b In nanomolars.
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isolate in PBMC was not associated with the acquisition of a
global sensitivity to neutralizing antibodies and entry inhib-
itors; the phenotypic changes were instead limited to the
CD4BS itself and, to a lesser extent, to the topologically
proximal epitope for the b12 MAb.Changes in the env gene are responsible for sCD4
sensitivity
To assess what might be the genetic cause of the
phenotypic change, we first sequenced the env genes from
viruses isolated during the PBMC culture of CC1/85. For
reasons of sample availability, we obtained genetic infor-
mation from a virus sample, CCcon.20, which was frozen
after 20 weeks, not 19. Analysis of the sequences from 12
individual clones showed that the only consistent changes
during the evolution of CCcon.20 were in the V2 loop of
gp120 (Fig. 4 and data not shown). Specifically, the orig-
inally dominant IRD sequence at positions 165–167 in
CC1/85 (seven of eight clones) was substituted by KRN
in all 12 CCcon.20 clones. These two changes increased the
positive charge of the V2 loop by adding a lysine and
removing an aspartic acid. The SN sequence at positions
188–189 of CC1/85 (seven of eight clones) was also deleted
in all 12 CCcon.20 clones, disrupting the canonical motif
NXT for glycosylation of residue N-189. Variants contain-
ing N-167 and lacking SN at positions 188 and 189 were
both present in the input CC1/85 virus population at low
frequency (one of eight clones in each case). Hence, these
minor variants were presumably selected for during the
prolonged PBMC culture (Fig. 4). However, none of the
sequenced CC1/85 input viruses contained K at position
165, so the appearance of this residue in CCcon.20 is due
either to a de novo mutation or the expansion of a variant
that was initially present at an undetectably low frequency
(<1 in 8 clones).
Fig. 3. The PTCA virus CCcon.19 has acquired sensitivity to sCD4 and MAb b12. Isolates CC1/85 (filled circles) and CCcon.19 (open circles) were tested for
their sensitivity in primary CD4+ T cells to (A) sCD4, (B) b12, (C) 2F5, (D) 4E10, (E) 2G12, and (F) T1249. The extent of virus replication is presented as a
percentage of p24 antigen production in the control culture (defined as 100%). The error bars represent the SEM of values from three independent experiments.
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from the CC1/85 culture at intermediate time points. By
passage 10, all of the 11 sequenced CCcon.10 clones
contained at least one of the I165K and D167N substitu-
tions, and 2 of the clones carried both changes (Fig. 4). The
glycosylation site at position 189 was also absent from 10 of
the 11 CCcon.10 clones. Hence, 2 of the 11 CCcon.10
clones carried all three changes that were later found in all
12 of the CCcon.20 clones (Fig. 4). The double and triple
mutants could have arisen either via recombination or
through serial base substitution and deletion. None of the
V2 changes were present in the AD101 escape mutant
isolate CC101.19, consistent with its retention of sCD4resistance (data not shown) (Kuhmann et al., in press;
Trkola et al., 2002).
To assess whether the above changes in the V2 loop were
sufficient to account for the phenotypic differences between
CC1/85 and CCcon.19, we first created chimeric viruses
based on HIV-1 NL4-3. These chimeras contained various
env genes cloned from the isolates but were otherwise
isogenic. The env gene of CC1/85 isolate displayed consid-
erable sequence heterogeneity, so we made four infectious
chimeras from this virus to try to cover the range of possible
genotypes present. Because the sequence of the CCcon.19
isolate was much more homogenous, a single infectious
chimera was deemed sufficient for an analysis of its prop-
Fig. 4. Comparison of the gp120 V2 sequences from the CC1/85, CCcon.10, and CCcon.20 isolates. The top line shows the consensus V2 sequence of the
CC1/85 isolate based on eight clones. The locations and numbers of specific amino acids, based on the HXBc2 sequence, are shown above the consensus line.
For each clone, identity to the consensus sequence is designated by a dash, while periods indicate deletions and letters denote substitutions. Amino acid
changes that appear to be selected for in the CCcon.10 and CCcon.20 viruses are highlighted in bold.
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PBMC frozen from the week-20 passage, and is designated
CCcon.20 cl.11; we judged that the properties of CCcon.19
and CCcon.20 viruses would be very similar and most
probably identical.
All five chimeric molecular clones were replication
competent. Among the four CC1/85 clones tested, one of
them, CC1/85 cl.7, was partially sensitive to sCD4 (IC50,
1.1 Ag/ml). The others, CC1/85 cl.6, CC1/85 cl.8, and CC1/
85 cl.10, were fully resistant (Fig. 5A, Table 2). Of note is
that CC1/85 cl.7 is the only one to contain residue N-167, as
opposed to the more common D-167 (Fig. 4). The
CCcon.20 cl.11 virus was sCD4-sensitive (IC50, 0.04 Ag/
ml). Hence, not surprisingly, the determinants of sCD4
sensitivity lie within the env gene.
Site-directed mutagenesis of specific residues in the V2 loop
As noted above, the V2 loop of gp120 was the only
region of Env where there were consistent differences
between CC1/85 and CCcon.20 (Fig. 4). Furthermore, the
partially sCD4-sensitive CC1/85 cl.7 virus was the only one
of the four infectious CC1/85 clones to possess residue N-167 instead of the more common D-167 variant (Fig. 4). To
assess whether this and other changes in the V2 region were
responsible for sCD4 sensitivity, we made point substitu-
tions in the env genes of the CC1/85 and CCcon.20 chimeric
virus clones.
We first changed the IRD sequence at positions 165–
167 in the sCD4-resistant CC1/85 cl.6 to the KRN motif
found in the sCD4-sensitive CCcon.20 cl.11 virus to make
the CC1/85 cl.6 KRN mutant. These changes caused a
significant increase in sCD4 sensitivity, albeit not to the
extent possessed by CCcon.20 cl.11 (Fig. 5B, Table 2).
When back-substitutions were made in CCcon.20 cl.11, the
single changes K165I (CCcon.20 cl.11 IRN) and N167D
(CCcon.20 cl.11 KRD) were each sufficient to cause a 50-
fold decrease in sCD4 sensitivity (Fig. 5C, Table 2).
Moreover, the double mutant (CCcon.20 cl.11 IRD), con-
taining both the K165I and the N167D changes, was 100-
fold less sensitive to sCD4 (Fig. 5C, Table 2). Hence, this
V2 loop motif has a substantial influence on sCD4
resistance.
We next introduced the N167D substitution into the
partially sCD4-sensitive CC1/85 cl.7 virus to make CC/85
cl.7 IRD. This change was sufficient to convert the viral
Fig. 5. Determinants of sCD4 sensitivity lie in the V2 region of HIV-1
gp120. Chimeric molecular clones were tested for sCD4 sensitivity in
primary CD4+ T cells. The extent of virus replication is presented as a
percentage of p24 antigen production in the control cultures (defined as
100%). One representative experiment out of three is shown.
Table 2
Inhibition of HIV-1 clones by sCD4 in primary CD4+ T cells
Virus sCD4 IC50 (Ag/ml)a
CC1/85 cl.6 (IRD) >50
CC1/85 cl.7 (IRN) 1.1
CC1/85 cl.8 (IRD) >50
CC1/85 cl.10 (IRD) >50
CCcon.20 cl.11 (KRN) 0.04
CC1/85 cl.6 KRNDSN 0.1
CC1/85 cl.6 KRN 1.0
CC1/85 cl.6 IRN >50
CC1/85 cl.7 IRD >50
CCcon.20 cl.11 KRD 1.1
CCcon.20 cl.11 IRN 1.2
CCcon.20 cl.11 IRD 3.1
CC1/85 cl.6 DSN >50
CCcon.20 cl.11 SN 0.04
a IC50 values for sCD4 inhibition curves were interpolated by fitting the
data to a sigmoidal curve.
P. Pugach et al. / Virology 321 (2004) 8–2214phenotype to complete sCD4 resistance (Fig. 5A, Table 2).
However, making the converse D167N substitution in the
sCD4-resistant CC1/85 cl.6 virus to create the CC1/85 cl.6
IRN clone did not create sCD4 sensitivity (Fig. 5B, Table
2). Thus, changes at residue 167 influence sCD4 sensitivity,
but are not themselves sufficient to determine the overall
phenotype.
In contrast, changes in CC1/85 cl.6 and CCcon.20 cl.11
that caused the deletion or insertion of the SN motif atpositions 188–189, and the associated glycosylation site,
had no direct influence on sCD4 sensitivity or resistance
(Figs. 5B, C, Table 2). However, because the CC1/85 cl.6
KRN mutant was not fully sensitive to sCD4, we made the
triple mutant CC1/85 cl.6 KRNDSN to see whether the
presence or absence of the glycosylation site at position N-
189 indirectly influenced the phenotype. This triple mutant
was as sensitive as CCcon.20 cl.11 to sCD4 (Fig. 5B, Table
2). Hence, the deletion of the SN sequence was necessary
for complete sCD4 sensitivity, but only in the context of
additional changes at residues 165–167.
CCcon.19 uses CD4 more efficiently
Because sCD4 was not present in the PBMC cultures,
the acquisition of sCD4 sensitivity by CC1/85 must be
secondary to a related change in viral phenotype that had
other causes. It can be presumed that these reasons relate
to increases in replication efficiency. One plausible expla-
nation is that the interaction between virion-associated Env
and cell surface CD4 became more efficient in culture,
with a consequent but coincidental rise in the virion
binding of sCD4. If so, then we reasoned that the sCD4-
sensitive CCcon.19 virus should be less sensitive to
inhibition by anti-CD4 MAbs; the MAbs should be less
able to compete with the higher affinity interaction be-
tween CCcon.19 Env and cell surface CD4. To test this
hypothesis, we determined the sensitivities of the CC1/85
and CCcon.19 isolates to anti-CD4 MAbs L222, 13B.8.2,
Q4120, and PA2. Compared to CC1/85, the CCcon.19
virus was relatively resistant to all of these MAbs, by 7- to
>40-fold (Figs. 6A, B, Table 1).
We also performed an ELISA using gp120 expressed
from CCcon.20 and CC1/85 clones to assess whether the
altered interaction between the CCcon.20 virus and CD4
was manifested at the level of monomeric gp120. In this
assay, there was no difference in the binding of CD4-IgG2
to gp120 from CCcon.20 cl.11 compared to gp120s from
Table 3
Replication of CC1/85 and CCcon.19 in CD4+ T cells and macrophages
log (TCID50 macrophages)/log(TCID50 CD4
+ T cells)
Isolate Donor 1 Donor 2 Donor 3
Day
7
Day
14
Day
21
Day
7
Day
14
Day
21
Day
7
Day
14
Day
21
CC1/85 0.00 0.00 0.67 0.00 0.23 0.63 0.67 0.67 0.96
CCcon.19 0.00 0.44 0.86 0.41 1.03 1.03 0.71 0.86 1.10
Values represent the ratio of infectious titers derived from macrophages and
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maximal CD4-IgG2 binding concentrations for the three
gp120s were 103, 100, and 57 ng/ml, respectively, which
we consider to be comparable. The difference in the CD4
interaction of the CCcon.19 and CCcon.20 viruses com-
pared to CC1/85 must therefore be due to changes in Env
structure that operate at the level of native Env, and not
monomeric gp120, as has generally been found in studies
of sCD4 sensitivity changes (Ashkenazi et al., 1991;
CD4+ T cells for the indicated viruses on days 7, 14, and 21.
Fig. 6. CCcon.19 has evolved resistance to anti-CD4 MAbs without altering
the affinity of monomeric gp120 for CD4. Isolates CC1/85 (open circles)
and CCcon.19 (filled squares) were tested for their sensitivity in primary
CD4+ T cells to (A) MAb Q4120 and (B) MAb PA2. The extent of virus
replication is presented as a percentage of p24 antigen production in the
control culture (defined as 100%). (C) The binding of CD4-IgG2 to gp120
derived from clones CC1/85 cl.6 (closed circles), CCcon.20 cl.11 (open
triangles), and CC1/85 cl.7 (closed squares) was measured by ELISA. The
error bars represent the SEM of values from three independent experiments.Brighty et al., 1991; Moore et al., 1992; Turner et al.,
1992).
Replication of CCcon.19 in macrophages
To determine whether CCcon.19 had expanded its cell
tropism compared to CC1/85, we measured the ability of
both viruses to infect macrophages. There was a modest
increase in the virus titer derived from macrophages infected
with CCcon.19 compared to CC1/85 (Table 3). Thus,
passage of the CC1/85 isolate in primary cells did increase
its capacity for replication in macrophages. The levels of
CD4 and CCR5 are significantly lower on macrophages
compared to CD4+ T cells (Di Marzio et al., 1998; Lee et al.,
1999; Lewin et al., 1996; Tuttle et al., 1998). Hence, the
above results are consistent with CCcon.19 having acquired
a greater affinity for CD4 during passage. We could detect
no difference in the entry efficiencies of the two isolates.
However, we suspect that any increase in the efficiency of
CCcon.19 entry is minor because it took over 10 weeks, or
35 replication cycles, in culture for the selective advantage
of the preexisting variants in the viral population to become
apparent (Fig. 4).Discussion
Significant phenotypic changes occur when HIV-1 adapts
to growth in T-cell lines, including the acquisition of
abnormal sensitivity to NAbs (Moore and Ho, 1995).
Neutralization resistance is required for viral persistence in
the face of humoral immunity in vivo, but is lost upon in
vitro adaptation. It has been argued that the various defense
mechanisms used to ward off the binding of NAbs in vivo
carry a price tag: a reduction in the rate of receptor-binding
and fusion (Moore and Ho, 1995). Most NAbs impair Env–
receptor interactions (Ugolini et al., 1997), so it seems
plausible that mechanisms hindering antibody binding
would also impede the attachment of similarly sized recep-
tors to closely proximal gp120 sites. A different, but not
mutually exclusive, possibility is that adaptation to T-cell
lines reflects an adjustment to their reduced CD4 expression
compared to primary CD4+ T cells in vitro and in vivo (Platt
et al., 2000). Thus, a selection pressure may favor Env
variants with a higher CD4 affinity when HIV-1 is cultured
P. Pugach et al. / Virology 321 (2004) 8–2216on T-cell lines, and the altered Env structures may, coinci-
dentally, have more exposed neutralization epitopes, partic-
ularly those associated with the CD4BS (Platt et al., 2000).
Under both scenarios, the characteristic increase in the
sensitivity of TCLA viruses to sCD4 is coincidental to
Env alterations that open up the CD4BS but that would be
disfavored in the face of an effective humoral response in
vivo. Resistance to sCD4 is itself a consequence of the
natural mechanisms used in vivo to thwart the actions of
NAbs to the CD4BS (Moore and Sweet, 1993; Moore et al.,
1993).
Although the above two scenarios are related, they can be
distinguished by their differing requirements for a reduced
CD4 density on target cells in vitro. If the primary driving
force for change is to reduce Env’s armor against NAbs, it
should not matter whether the CD4 density differs in vitro
and in vivo. However, if the dominant selection pressure is
for use of the lower CD4 levels on T-cell lines, neutraliza-
tion sensitivity would not arise in vitro when primary CD4+
T cells are the targets (Platt et al., 2000). Our demonstration
that a primary HIV 1 isolate can, in fact, acquire sCD4
sensitivity when cultured only on PBMC therefore shows
that a lower CD4 density is not obligatory for reduced
neutralization resistance.
The overall selection pressure on HIV 1 during in vitro
adaptation might still involve increasing its CD4 binding
efficiency, by altering the CD4BS configuration to increase
its accessibility to CD4 and, by coincidence, sCD4. The
acquired resistance of CCcon.19 to anti-CD4 D1 MAbs is
consistent with this hypothesis. Conversely, selection for
sCD4 and CD4-Ig resistance created increased sensitivity to
anti-CD4 D1 MAbs (Klasse and McKeating, 1993). The
modestly increased ability of CCcon.19 to replicate in
macrophages is also relevant; macrophages express less
CD4 than CD4+ T cells (Lee et al., 1999; Lewin et al.,
1996).
The neutralization-sensitive TCLA virus HIV-1 IIIB
became neutralization resistant after adaptation to growth
in an accidentally infected human (Beaumont et al., 2001).
The dominant selection pressure in vivo must have been for
NAb resistance. However, when NAbs are absent, either in
vitro or when the immune system is substantially impaired,
the balance shifts away from the need for protection. HIV-1
and SIV variants with increased replication competence
evolve in the later stages of infection in vivo (Kimata et
al., 1999; Kwa et al., 2003). Perhaps these phenotypic
changes reflect, at least in part, a relaxation in Env’s
defenses as the NAb response diminishes during disease
progression? In vitro, adaptations creating neutralization
sensitivity are not restricted to HIV-1, but occur also with
SIV, FIV, and EIAV (Baldinotti et al., 1994; Cook et al.,
1995; Means et al., 1997; Montefiori et al., 1998b). The
general principle of a balance between binding cellular
receptors and NAbs would be fundamental to all persistent
lentiviruses, irrespective of their specific receptor(s). Hence,
different viruses might respond similarly to replication incell lines that differ significantly from the natural target cells
in respect of the concentrations and identities of cell surface
receptors and attachment factors (Ibrahim et al., 1999;
Mondor et al., 1998; Patel et al., 1993; Spenlehauer et al.,
2001). The efficiency of envelope glycoproteins incorpora-
tion into the virion may be another factor that could vary
with the producer cell, and this too could affect the neutral-
ization sensitivity of any lentivirus (Klasse and Moore,
1996).
Previous studies on HIV-1 adaptation in vitro have been
complicated by co-receptor switching or selection during the
process. Most T-cell lines express CXCR4 but lack CCR5,
whereas CCR5 is more commonly used in vivo (Clapham
and McKnight, 2002; Doms, 2000; Moore et al., in press;
Pohlmann and Doms, 2002). Isolation of HIV-1 on activated
PBMC usually favors R5 virus replication; on T-cell lines,
X4 viruses (Moore et al., in press). Hence, TCLAviruses are
not just neutralization-sensitive, they differ in co-receptor
usage from most primary isolates. Most, but not all, studies
indicate that co-receptor usage is not a major influence on
neutralization sensitivity; primary X4 and R5 isolates all
tend to be neutralization-resistant (LaCasse et al., 1998;
Montefiori et al., 1998a; Polonis et al., 2003; Trkola et al.,
1998a). However, it remained possible that an adapted virus
would acquire neutralization sensitivity in vitro only if it
used CXCR4. Clearly, we now show this is not the case.
The sCD4-sensitive, PBMC-adapted virus CCcon.19
retained its original R5 phenotype, and does not use
CXCR4. The acquisition of sCD4 sensitivity is not, there-
fore, just a consequence of T-cell line adaptation, it can
occur after prolonged in vitro passage in primary cells and
without co-receptor switching. The R5 PTCA variant has at
least one property, sCD4 sensitivity, resembling those of
classical X4 TCLA viruses. Hence, HIV-1 ‘‘laboratory
adaptation’’ can involve more than just a switch in co-
receptor usage or selection of variants that use only CXCR4.
Whether this will be true of all PTCA viruses remains to be
determined.
Most TCLA viruses have acquired an epitope-indepen-
dent, global sensitivity to NAbs. This applies even to anti-
gp41 NAbs that act after receptor binding (Moulard et al.,
2002). It is still not fully understood why. Studies on one
experimental system suggest that changes in the gp41–
gp120 interaction can be associated with an increased
exposure of multiple antibody epitopes (Park and Quinnan,
1999; Park et al., 2000). However, changes in only the V2
loop were observed in the PTCA virus CCcon.19. It became
more sensitive to sCD4 and, to a lesser extent, the CD4BS
MAb, b12, but not to NAbs 2G12, 2F5, and 4E10. Hence,
the underlying mechanism is specific to the CD4BS, but
even here its effect is limited as CCcon.19 did not become
sensitive to CD4BS MAbs 205-42-15, 205-43-1, and 205-
46-9. Acquisition of global neutralization sensitivity is not,
therefore, an obligatory consequence of in vitro adaptation.
The entry inhibitors AD101, SCH-C, and T-1249 had
similar potencies against the PTCA virus CCcon.19 and the
Table 4
Variation in residues 165–167 of HIV-1 gp120 during adaptation to
replication in vitro
Parental
straina
Tropismb Residues
165–167
(Pre)c
Adaptation
systemd
Residues
165–167
(post)e
Referencef
Case
C1/85
R5 IRD PBMC KRN present study
JRCSF R5 IRD PBMC IRN Mo et al., 1997
MN X4 IRD H9 IGN Bouma et al.,
2003
168P X4 IRD H9 RRD Wrin et al., 1995
320SI X4 IRD MT4/H9 KRD Follis et al., 1998
IIIB X4 IRG in vivo
(human)
IKG Beaumont
et al., 2001
SHIV
vpu+
X4 IRG in vivo
(macaque)
IGE Hofmann-
Lehmann
et al., 2002
a Virus designation.
b Tropism (R5 or X4).
c Identity of residues 165–167 (HxB2 numbering system) before adaptation.
d Experimental system used for adaptation.
e Identity of residues 165–167 after adaptation.
f Source of information.
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rates directly, other studies imply that the overall fusion
kinetics of CCcon.19 will probably not be significantly
altered by its acquisition of sCD4 sensitivity (Reeves et
al., 2002). The unaltered sensitivity to AD101, SCH-C, and
T-1249 is consistent with their known actions at stages after
CD4 binding (Melikyan et al., 2000; Moore and Doms,
2003).
Genetic sequencing revealed that the only consistent
differences between CC1/85 and CCcon.20 were in V2,
specifically at residues 165–167 and 188–189. The latter
change eliminates a canonical N-linked glycan site. The
gradual evolution of these changes is apparent by inspection
of sequences of viruses from passage 10 (Fig. 4). Between
CC1/85 and CCcon.20, there were no relevant sequence
alterations in the gp120 core. This is not surprising because
the core sequences of primary and TCLA viruses are very
similar (Kwong et al., 2000). However, the variable loops in
general and the V2 domain in particular are major determi-
nants of the TCLA phenotype. For example, grafting the
V1/V2 loop structure from a primary virus onto a TCLA
strain creates a chimeric virus with properties resembling
those of the primary virus (Koito et al., 1994; Morikita et al.,
1997). One role of the V2 loop is to shield the underlying,
more conserved receptor binding sites from NAbs; the V2
loop is dispensable for HIV-1 replication in vitro, at least in
some cell types, but V2 loop-deleted viruses are very
neutralization-sensitive (Cao et al., 1997; Stamatatos et al.,
1998; Wyatt et al., 1995). The V2 loop conformation may
influence CD4 binding because of its predicted spatial
proximity to the recessed cavity that is a critical CD4BS
element (Wyatt et al., 1998). Several V2 residues influence
the binding of MAb b12, at least in the context of other
primary R5 viruses (Mo et al., 1997; Pantophlet et al.,
2003).
Substitutions at residues 165–167 during adaptation of
various HIV-1 strains to replication in vitro have been
reported previously (Table 4) (Beaumont et al., 2001;
Bouma et al., 2003; Follis et al., 1998; Hofmann-Lehmann
et al., 2002; Mo et al., 1997; Wrin et al., 1995). Overall,
adaptation is associated with an increase in the positive
charge of this amino acid motif: IRD to IRN (Mo et al.,
1997), IRD to IGN (Bouma et al., 2003), IRD to RRD (Wrin
et al., 1995), IRD to KRD (Follis et al., 1998). In our study,
the change was IRD to KRN, again increasing the positive
charge of the motif. Hence, different HIV-1 strains with
various phenotypes may take a similar genetic pathway
when adapting to growth in vitro. The D167N substitution
also arose in the JR-CSF strain when this virus became
resistant to MAb b12 in vitro (Mo et al., 1997). By itself,
that substitution was insufficient to confer b12 resistance,
just as it was not enough to confer b12 sensitivity in the
present study. Residue 167 may be involved in interactions
with other amino acids more proximal to the CD4BS and its
associated epitopes. Such an indirect influence would be
consistent with previous findings on the determinants ofneutralization sensitivity and resistance (Si et al., 2001; Ye
et al., 2000).
The gp120 protein is heavily glycosylated, which is one
of HIV-1’s NAb evasion and escape mechanisms (Johnson
and Desrosiers, 2002; Olofsson and Hansen, 1998; Reitter et
al., 1998; Wei et al., 2003). The loss of glycans can result in
faster replication kinetics, at least in vitro, particularly when
sites near the CD4BS are disrupted (Ohgimoto et al., 1998).
The glycan lost in CCcon.20 is thought likely to physically
abut the CD4BS (Wyatt et al., 1998). A plausible explana-
tion of the sequence changes in CC1/85 that create
CCcon.20 is, therefore, that they alter the geometry of the
V1/V2 loop structure in relation to the underlying CD4BS.
Both the loss of the glycan at position 189 and a change in
the positioning of the V1/V2 loop as a whole may be
relevant. The structural consequences are likely to be
manifested only at the level of the functional Env complex,
and inapparent from studies with monomeric gp120 from
HIV-1 (Ashkenazi et al., 1991; Brighty et al., 1991; Moore
et al., 1992; Turner et al., 1992) and HIV-2 (Mulligan et al.,
1992).
The principal driving force behind adaptation would be
the facilitation of cell surface CD4 binding, the increase in
sCD4 and b12 sensitivity arising from the increased acces-
sibility of the CD4BS and its associated epitopes to ligands.
In vivo, this effect would be countered by NAbs to CD4BS
epitopes. The ability of HIV-1 to replicate in cell types such
as the macrophage might also be relevant in vivo, particu-
larly when humoral immunity becomes impaired in the later
stages of infection (Igarashi et al., 2001). Macrophages
express less CD4 than T cells (Lee et al., 1999; Lewin et
al., 1996), so it is conceivable the Env complex might not
always be configured optimally for entry into both cell types
simultaneously. Any minor increments in replication effi-
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amplified over multiple cycles (Coffin, 1986). Overall, the
efficiency of HIV-1 entry in vivo is subject to the outcome
of the exquisite interplay of opposing influences on the
highly plastic configuration of the Env complex.Methods
Antibodies and other reagents
The CC-chemokine RANTES was obtained from Pepro-
Tech Inc. (Rocky Hill, NJ). The anti-CD4 MAb PA2, the
anti-gp120 MAb PA14, the sCD4 and CD4-IgG2 proteins,
and the gp41-based peptide T1249 were all gifts from Dr.
William Olson (Progenics, Tarrytown, NY) (Allaway et al.,
1995; Kilby and Eron, 2003; Olson et al., 1999). The anti-
Env MAbs 2F5, 4E10, and 2G12 were donated by Dr.
Hermann Katinger (Polymun Scientific Inc, Vienna, Austria)
(Trkola et al., 1995), the anti-gp120 MAb b12 by Dr. Dennis
Burton (Scripps Research Institute, La Jolla, CA) (Burton et
al., 1994), and the anti-gp120 MAbs 205-42-15, 205-43-1,
and 205-46-9 by Dr. Michael Fung (Tanox Inc, Houston,
TX) (Fouts et al., 1998). The anti-gp120 MAb 447-52D was
obtained from the AIDS Research and Reference Reagent
Program, NIAID, NIH, contributed by S. Zolla-Pazner. The
small molecule CCR5 and CXCR4 inhibitors AD101, SCH-
C, and AMD3100 were provided by Dr. Bahige Baroudy
(Schering Plough Research Institute, Kenilworth, NJ) (Don-
zella et al., 1998; Strizki et al., 2001; Trkola et al., 2002).
Anti-CD4 MAbs L222, Q4120, and 13B.8.2 were gifts from
Dr. Quentin Sattentau (Oxford University, UK) (Davis et al.,
1992; Healey et al., 1990; Sattentau et al., 1989).
Generation of the HIV-1 CC1/85 variant, CCcon.19
The R5 primary HIV-1 isolate CC1/85 was derived in
January 1985 from individual ‘‘Case C’’ who was enrolled
in a New York Blood Center cohort and shown retrospec-
tively to have become HIV-1 seropositive between October
1979 and February 1980 (Connor et al., 1993, 1997). The
conditions used to generate the CCcon.19 variant have been
described in detail elsewhere (Trkola et al., 2002). Briefly,
CC1/85 was added at one thousand 50% tissue culture
infectious doses (TCID50) per ml to 20 ml of mitogen-
activated PBMC (1  106/ml). The culture was passaged
weekly, using PBMC from a different, anonymous donor
each week. The production of p24 antigen was monitored
regularly to ensure that HIV-1 replication was occurring. At
least once every 2 weeks, the culture supernatant was frozen
for later sensitivity and co-receptor utilization studies.
Infection of CD4+ T cells and macrophages
Mitogen-activated, CD8+ T-cell-depleted PBMC (re-
ferred to hereafter as primary CD4+ T cells) were preparedfrom leukopacks pooled from the blood of four healthy
volunteers. The pooled fractions were treated with the
‘‘RosetteSep CD8+ depletion cocktail’’ (StemCell Technol-
ogies, Vancouver, BC, Canada) according to the manufac-
turer’s instructions, before Ficoll density gradient separation
of leukocytes to deplete CD8+ T cells from the PBMC by
rosette formation (Trkola et al., 1998b). The CD8+ T-cell-
depleted leukocytes were then stimulated as described
elsewhere (Trkola et al., 1998b) and used for HIV-1 repli-
cation assays 3 days later (Trkola et al., 2002).
Macrophages were isolated, then infected with HIV-1 as
described previously (Ketas et al., 2003). Culture super-
natants were harvested at days 7, 14, and 21 for measure-
ment of p24 antigen concentrations.
Cloning of env genes
env clones were named according to our previous no-
menclature (Trkola et al., 2002). Thus, CC1/85 is the
parental isolate, and CCcon.19 refers to the control virus
that was cultured for 19 passages in PBMC. The clones
generated and used here extend this nomenclature, such that
CC1/85 cl.XX refers to clone XX from the parental CC1/85
isolate. The nomenclature used to designate the other clones
generated in this study was also derived from that used
elsewhere (Kuhmann et al., in press; Trkola et al., 2002).
env genes were cloned into the vector pAMP1 using the
CloneAmp system for rapid cloning of amplification prod-
ucts (Invitrogen, Carlsbad, CA), according to the manufac-
turer’s instructions. The PCR products to be cloned were
generated by nested PCR from genomic DNA that was
isolated from infected PBMC by methods used previously
(Kuhmann et al., in press; Trkola et al., 2002). The GenBank
accession numbers for the sequences are AY357338 through
AY357345 (CC1/85), AY357464 through AY357469
(CC101.19), AY357525 through AY357535 (CCcon.10)
and AY357536 through AY357547 (CCcon.20).
Recombinant gp120 proteins from clones CC1/85 cl.6,
CC1/85 cl.7, and CCcon.20 cl.11 were produced as de-
scribed previously (Kuhmann et al., in press).
Construction of chimeric NL4-3/env proviruses and
site-directed mutagenesis
Chimeric proviruses were constructed from the pNL4-3
proviral plasmid (Adachi et al., 1986) (AIDS Research and
Reference Reagent Program, NIAID, NIH, contributed by
Dr. M. Martin) by overlapping PCR, described previously
(Kuhmann et al., in press).
Site-directed mutagenesis of the env clones was per-
formed with the QuickChange mutagenesis kit (Strata-
gene) according to the manufacturer’s instructions, using
the pBluescript(KS+) plasmids that contained the EcoRI
to XhoI fragments. All of these env constructs were
sequenced to confirm that the desired changes were
present without other mutations, then the EcoRI to XhoI
P. Pugach et al. / Virology 321 (2004) 8–22 19fragments were subcloned into pNL4-3 as described
above.
Infectivity of chimeric viruses
Clonal, replication-competent, chimeric NL4-3/env
viruses were prepared by transfection of 293T cells, which
were maintained in Dulbecco’s minimal essential medium
supplemented with 10% fetal bovine serum (complete
medium). Briefly, 15 Ag of the full-length proviral plasmid
was transfected into 1  107 293T cells using Lipofect-
amine 2000 (Invitrogen), according to the manufacturer’s
instructions. The cells were washed after 24 h, then fed
with complete medium. The supernatants were collected 48
h post-transfection, filtered through a 0.45-Am filter, and
stored in aliquots at 80 jC. These virus stocks were
titered on primary CD4+ T cells, then replication assays
were performed as described for standard HIV-1 isolates in
PBMC (Trkola et al., 2002), except that 3000 TCID50 per
ml of virus were used for infection. The culture super-
natants were analyzed for p24 production after 10 days.
The infectivities of viruses produced by transient transfec-
tion were determined on day 12 postinfection in primary
CD4+ T cells, and ranged from 1  104 to 1  105
TCID50/ml of viral supernatant. In addition, the p24
production in the primary CD4+ T-cell replication assays
was similar for all the clonal viruses used in this study,
typically 5–10 ng/ml of p24.
Binding of gp120 to CD4-IgG2
The gp120 capture enzyme-linked immunsorbent assays
(ELISA) were performed essentially as described elsewhere
(Moore and Sodroski, 1996). The gp120 proteins were
captured at saturating concentrations to plastic plates coated
with the sheep polyclonal antibody D7324 to the C-terminus
of gp120, then the binding of CD4-IgG2 was detected
(Moore and Sodroski, 1996). The background OD490 signal
(no gp120) was subtracted from the signal derived using
gp120 at each input MAb or CD4-IgG2 concentration. The
net OD492 value obtained at 10 Ag/ml of CD4-IgG2 was
defined as 100% for normalization purposes.Acknowledgments
We thank Bahige Baroudy, Dennis Burton, Michael
Fung, Hermann Katinger, Bill Olson, and Quentin Sattentau
for gifts of reagents, and Alexandra Trkola for her role in the
initiation of the CC1/85 culture. We appreciate receiving
critical comments on the manuscript from P.J.Klasse. This
work was supported by Grants R37 AI36082, RO1
AI39420, and RO1 AI41420, by NIH Immunology Training
Grant T32 AI07621 (P.P., S.E.K.), and by the International
AIDS Vaccine Initiative. J.P.M. is a Stavros S. Niarchos
Scholar. The Department of Microbiology and Immunologyat the Weill Medical College gratefully acknowledges the
support of the William Randolph Hearst Foundation.References
Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson,
A., Martin, M.A., 1986. Production of acquired immunodeficiency
syndrome-associated retrovirus in human and nonhuman cells trans-
fected with an infectious molecular clone. J. Virol. 59 (2), 284–291.
Allaway, G.P., Davis-Bruno, K.L., Beaudry, G.A., Garcia, E.B., Wong, E.L.,
Ryder, A.M., Hasel, K.W., Gauduin, M.C., Koup, R.A., McDougal, J.S.,
Maddon, P.J., 1995. Expression and characterization of CD4-IgG2, a
novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS
Res. Hum. Retroviruses 11 (5), 533–539.
Arendrup, M., Sonnerborg, A., Svennerholm, B., Akerblom, L., Nielsen,
C., Clausen, H., Olofsson, S., Nielsen, J.O., Hansen, J.E., 1993. Neu-
tralizing antibody response during human immunodeficiency virus
type 1 infection: type and group specificity and viral escape. J. Gen.
Virol. 74, 855–863.
Ashkenazi, A., Smith, D.H., Marsters, S.A., Riddle, L., Gregory, T.J., Ho,
D.D., Capon, D.J., 1991. Resistance of primary isolates of human im-
munodeficiency virus type 1 to soluble CD4 is independent of CD4–
rgp120 binding affinity. Proc. Natl. Acad. Sci. U.S.A. 88 (16),
7056–7060.
Baldinotti, F., Matteucci, D., Mazzetti, P., Giannelli, C., Bandecchi, P.,
Tozzini, F., Bendinelli, M., 1994. Serum neutralization of feline immu-
nodeficiency virus is markedly dependent on passage history of the
virus and host system. J. Virol. 68 (7), 4572–4579.
Beaumont, T., van Nuenen, A., Broersen, S., Blattner, W.A., Lukashov, V.V.,
Schuitemaker, H., 2001. Reversal of human immunodeficiency virus
type 1 IIIB to a neutralization-resistant phenotype in an accidentally
infected laboratory worker with a progressive clinical course. J. Virol.
75 (5), 2246–2252.
Berger, E.A., Murphy, P.M., Farber, J.M., 1999. Chemokine receptors as
HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev.
Immunol. 17, 657–700.
Binley, J.M., Klasse, P.J., Cao, Y., Jones, I., Markowitz, M., Ho, D.D.,
Moore, J.P., 1997. Differential regulation of the antibody responses
to Gag and Env proteins of human immunodeficiency virus type 1.
J. Virol. 71 (4), 2799–2809.
Bouma, P., Leavitt, M., Zhang, P.F., Sidorov, I.A., Dimitrov, D.S., Quinnan
Jr., G.V., 2003. Multiple interactions across the surface of the gp120
core structure determine the global neutralization resistance phenotype
of human immunodeficiency virus type 1. J. Virol. 77 (14), 8061–8071.
Brighty, D.W., Rosenberg, M., Chen, I.S., Ivey-Hoyle, M., 1991. Enve-
lope proteins from clinical isolates of human immunodeficiency virus
type 1 that are refractory to neutralization by soluble CD4 possess
high affinity for the CD4 receptor. Proc. Natl. Acad. Sci. U.S.A. 88
(17), 7802–7805.
Burton, D.R., 2002. Antibodies, viruses and vaccines. Nat. Rev., Immunol.
2 (9), 706–713.
Burton, D.R., Pyati, J., Koduri, R., Sharp, S.J., Thornton, G.B., Parren,
P.W., Sawyer, L.S., Hendry, R.M., Dunlop, N., Nara, P.L., Lamacchia,
P., Garratty, E., Stiehm, E.R., Bryson, Y.J., Cao, Y., Moore, J.P., Ho,
D.D., Barbas, C.F., 1994. Efficient neutralization of primary isolates
of HIV-1 by a recombinant human monoclonal antibody. Science 266
(5187), 1024–1027.
Cao, J., Sullivan, N., Desjardin, E., Parolin, C., Robinson, J., Wyatt, R.,
Sodroski, J., 1997. Replication and neutralization of human immuno-
deficiency virus type 1 lacking the V1 and V2 variable loops of the
gp120 envelope glycoprotein. J. Virol. 71 (12), 9808–9812.
Cheingsong-Popov, R., Panagiotidi, C., Bowcock, S., Aronstam, A., Wads-
worth, J., Weber, J., 1991. Relation between humoral responses to HIV
gag and env proteins at seroconversion and clinical outcome of HIV
infection. BMJ 302 (6767), 23–26.
P. Pugach et al. / Virology 321 (2004) 8–2220Cheng-Mayer, C., Brown, A., Harouse, J., Luciw, P.A., Mayer, A.J., 1999.
Selection for neutralization resistance of the simian/human immunode-
ficiency virus SHIVSF33A variant in vivo by virtue of sequence
changes in the extracellular envelope glycoprotein that modify N-linked
glycosylation. J. Virol. 73 (7), 5294–5300.
Clapham, P.R., McKnight, A., 2002. Cell surface receptors, virus entry and
tropism of primate lentiviruses. J. Gen. Virol. 83 (Pt 8), 1809–1829.
Coffin, J.M., 1986. Genetic variation in AIDS viruses. Cell 46 (1), 1–4.
Connor, R.I., Mohri, H., Cao, Y., Ho, D.D., 1993. Increased viral burden
and cytopathicity correlate temporally with CD4+ T-lymphocyte decline
and clinical progression in human immunodeficiency virus type 1-
infected individuals. J. Virol. 67 (4), 1772–1777.
Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S., Landau, N.R., 1997.
Change in coreceptor use correlates with disease progression in HIV-1-
infected individuals. J. Exp. Med. 185 (4), 621–628.
Cook, R.F., Berger, S.L., Rushlow, K.E., McManus, J.M., Cook, S.J.,
Harrold, S., Raabe, M.L., Montelaro, R.C., Issel, C.J., 1995. Enhanced
sensitivity to neutralizing antibodies in a variant of equine infectious
anemia virus is linked to amino acid substitutions in the surface unit
envelope glycoprotein. J. Virol. 69 (3), 1493–1499.
Daar, E.S., Li, X.L., Moudgil, T., Ho, D.D., 1990. High concentrations of
recombinant soluble CD4 are required to neutralize primary human
immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. U.S.A.
87 (17), 6574–6578.
Davis, S.J., Schockmel, G.A., Somoza, C., Buck, D.W., Healey, D.G.,
Rieber, E.P., Reiter, C., Williams, A.F., 1992. Antibody and HIV-1
gp120 recognition of CD4 undermines the concept of mimicry between
antibodies and receptors. Nature 358 (6381), 76–79.
Di Marzio, P., Tse, J., Landau, N.R., 1998. Chemokine receptor regulation
and HIV type 1 tropism in monocyte-macrophages. AIDS Res. Hum.
Retroviruses 14 (2), 129–138.
Doms, R.W., 2000. Beyond receptor expression: the influence of receptor
conformation, density, and affinity in HIV-1 infection. Virology 276 (2),
229–237.
Donzella, G.A., Schols, D., Lin, S.W., Este, J.A., Nagashima, K.A., Mad-
don, P.J., Allaway, G.P., Sakmar, T.P., Henson, G., De Clercq, E.,
Moore, J.P., 1998. AMD3100, a small molecule inhibitor of HIV-1
entry via the CXCR4 co-receptor. Nat. Med. 4 (1), 72–77.
Etemad-Moghadam, B., Sun, Y., Nicholson, E.K., Fernandes, M., Liou, K.,
Gomila, R., Lee, J., Sodroski, J., 2000. Envelope glycoprotein determi-
nants of increased fusogenicity in a pathogenic simian–human immu-
nodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 74 (9),
4433–4440.
Follis, K.E., Trahey, M., LaCasse, R.A., Nunberg, J.H., 1998. Continued
utilization of CCR5 coreceptor by a newly derived T-cell line-adapted
isolate of human immunodeficiency virus type 1. J. Virol. 72 (9),
7603–7608.
Fouts, T.R., Trkola, A., Fung, M.S., Moore, J.P., 1998. Interactions of
polyclonal and monoclonal anti-glycoprotein 120 antibodies with olig-
omeric glycoprotein 120–glycoprotein 41 complexes of a primary HIV
type 1 isolate: relationship to neutralization. AIDS Res. Hum. Retro-
viruses 14 (7), 591–597.
Gomatos, P.J., Stamatos, N.M., Gendelman, H.E., Fowler, A., Hoover, D.L.,
Kalter, D.C., Burke, D.S., Tramont, E.C., Meltzer, M.S., 1990. Relative
inefficiency of soluble recombinant CD4 for inhibition of infection by
monocyte-tropic HIV in monocytes and T cells. J. Immunol. 144 (11),
4183–4188.
Healey, D., Dianda, L., Moore, J.P., McDougal, J.S., Moore, M.J., Estess,
P., Buck, D., Kwong, P.D., Beverley, P.C., Sattentau, Q.J., 1990. Novel
anti-CD4 monoclonal antibodies separate human immunodeficiency vi-
rus infection and fusion of CD4+ cells from virus binding. J. Exp. Med.
172 (4), 1233–1242.
Herrera, C., Spenlehauer, C., Fung, M.S., Burton, D.R., Beddows, S.,
Moore, J.P., 2003. Nonneutralizing antibodies to the CD4-binding site
on the gp120 subunit of human immunodeficiency virus type 1 do not
interfere with the activity of a neutralizing antibody against the same
site. J. Virol. 77 (2), 1084–1091.Hofmann-Lehmann, R., Vlasak, J., Chenine, A.L., Li, P.L., Baba, T.W.,
Montefiori, D.C., McClure, H.M., Anderson, D.C., Ruprecht, R.M.,
2002. Molecular evolution of human immunodeficiency virus env in
humans and monkeys: similar patterns occur during natural disease
progression or rapid virus passage. J. Virol. 76 (10), 5278–5284.
Ibrahim, J., Griffin, P., Coombe, D.R., Rider, C.C., James, W., 1999. Cell-
surface heparan sulfate facilitates human immunodeficiency virus type
1 entry into some cell lines but not primary lymphocytes. Virus Res. 60
(2), 159–169.
Igarashi, T., Brown, C.R., Endo, Y., Buckler-White, A., Plishka, R., Bis-
chofberger, N., Hirsch, V., Martin, M.A., 2001. Macrophage are the
principal reservoir and sustain high virus loads in rhesus macaques after
the depletion of CD4+ T cells by a highly pathogenic simian immuno-
deficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1
infections of humans. Proc. Natl. Acad. Sci. U.S.A. 98 (2), 658–663.
Johnson, W.E., Desrosiers, R.C., 2002. Viral persistance: HIV’s strategies
of immune system evasion. Annu. Rev. Med. 53, 499–518.
Johnson, W.E., Morgan, J., Reitter, J., Puffer, B.A., Czajak, S., Doms, R.W.,
Desrosiers, R.C., 2002. A replication-competent, neutralization-sensi-
tive variant of simian immunodeficiency virus lacking 100 amino acids
of envelope. J. Virol. 76 (5), 2075–2086.
Johnson, W.E., Lifson, J.D., Lang, S.M., Johnson, R.P., Desrosiers, R.C.,
2003. Importance of B-cell responses for immunological control of
variant strains of simian immunodeficiency virus. J. Virol. 77 (1),
375–381.
Ketas, T.J., Klasse, P.J., Spenlehauer, C., Nesin, M., Frank, I., Pope, M.,
Strizki, J.M., Reyes, G.R., Baroudy, B.M., Moore, J.P., 2003. Entry
inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication
in multiple cell types. AIDS Res. Hum. Retroviruses 19 (3), 177–186.
Kilby, J.M., Eron, J.J., 2003. Novel therapies based on mechanisms of HIV-
1 cell entry. N. Engl. J. Med. 348 (22), 2228–2238.
Kimata, J.T., Kuller, L., Anderson, D.B., Dailey, P., Overbaugh, J., 1999.
Emerging cytopathic and antigenic simian immunodeficiency virus var-
iants influence AIDS progression. Nat. Med. 5 (5), 535–541.
Kinter, A., Catanzaro, A., Monaco, J., Ruiz, M., Justement, J., Moir, S.,
Arthos, J., Oliva, A., Ehler, L., Mizell, S., Jackson, R., Ostrowski, M.,
Hoxie, J., Offord, R., Fauci, A.S., 1998. CC-chemokines enhance the
replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal
transduction. Proc. Natl. Acad. Sci. U.S.A. 95 (20), 11880–11885.
Klasse, P.J., McKeating, J.A., 1993. Soluble CD4 and CD4 immunoglob-
ulin-selected HIV-1 variants: a phenotypic characterization. AIDS Res.
Hum. Retroviruses 9 (7), 595–604.
Klasse, P.J., Moore, J.P., 1996. Quantitative model of antibody- and soluble
CD4-mediated neutralization of primary isolates and T-cell line-adapted
strains of human immunodeficiency virus type 1. J. Virol. 70 (6),
3668–3677.
Koito, A., Harrowe, G., Levy, J.A., Cheng-Mayer, C., 1994. Functional
role of the V1/V2 region of human immunodeficiency virus type 1
envelope glycoprotein gp120 in infection of primary macrophages
and soluble CD4 neutralization. J. Virol. 68 (4), 2253–2259.
Kozak, S.L., Platt, E.J., Madani, N., Ferro Jr., F.E., Peden, K., Kabat, D.,
1997. CD4, CXCR-4, and CCR-5 dependencies for infections by pri-
mary patient and laboratory-adapted isolates of human immunodeficien-
cy virus type 1. J. Virol. 71 (2), 873–882.
Kuhmann, S.E., Pugach, P., Taylor, J., Stanfield, R.L., Snyder, A., Strizki,
J.M., Reyes, G.R., Baroudy, B.M., Wilson, I.A., Korber, B., Wolinsky,
S.M., Moore, J.P., 2004. Genetic and phenotypic analyses of HIV-1
escape from a small molecule CCR5 antagonist. J. Virol. 78 (6)
(in press).
Kwa, D., Vingerhoed, J., Boeser, B., Schuitemaker, H., 2003. Increased in
vitro cytopathicity of CC chemokine receptor 5-restricted human im-
munodeficiency virus type 1 primary isolates correlates with a progres-
sive clinical course of infection. J. Infect. Dis. 187 (9), 1397–1403.
Kwong, P.D., Wyatt, R., Majeed, S., Robinson, J., Sweet, R.W., Sodroski,
J., Hendrickson, W.A., 2000. Structures of HIV-1 gp120 envelope gly-
coproteins from laboratory-adapted and primary isolates. Struct. Fold.
Des. 8 (12), 1329–1339.
P. Pugach et al. / Virology 321 (2004) 8–22 21LaCasse, R.A., Follis, K.E., Moudgil, T., Trahey, M., Binley, J.M., Pla-
nelles, V., Zolla-Pazner, S., Nunberg, J.H., 1998. Coreceptor utilization
by human immunodeficiency virus type 1 is not a primary determinant
of neutralization sensitivity. J. Virol. 72 (3), 2491–2495.
Lee, B., Sharron, M., Montaner, L.J., Weissman, D., Doms, R.W., 1999.
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte sub-
sets, dendritic cells, and differentially conditioned monocyte-derived
macrophages. Proc. Natl. Acad. Sci. U.S.A. 96 (9), 5215–5220.
Lewin, S.R., Sonza, S., Irving, L.B., McDonald, C.F., Mills, J., Crowe, S.M.,
1996. Surface CD4 is critical to in vitro HIV infection of human alveolar
macrophages. AIDS Res. Hum. Retroviruses 12 (10), 877–883.
Means, R.E., Greenough, T., Desrosiers, R.C., 1997. Neutralization sensi-
tivity of cell culture-passaged simian immunodeficiency virus. J. Virol.
71 (10), 7895–7902.
Melikyan, G.B., Markosyan, R.M., Hemmati, H., Delmedico, M.K., Lam-
bert, D.M., Cohen, F.S., 2000. Evidence that the transition of HIV-1
gp41 into a six-helix bundle, not the bundle configuration, induces
membrane fusion. J. Cell Biol. 151 (2), 413–423.
Mo, H., Stamatatos, L., Ip, J.E., Barbas, C.F., Parren, P.W., Burton, D.R.,
Moore, J.P., Ho, D.D., 1997. Human immunodeficiency virus type 1
mutants that escape neutralization by human monoclonal antibody
IgG1b12. J. Virol. 71 (9), 6869–6874.
Mondor, I., Ugolini, S., Sattentau, Q.J., 1998. Human immunodeficiency
virus type 1 attachment to HeLa CD4 cells is CD4 independent and
gp120 dependent and requires cell surface heparans. J. Virol. 72 (5),
3623–3634.
Montefiori, D.C., Collman, R.G., Fouts, T.R., Zhou, J.Y., Bilska, M.,
Hoxie, J.A., Moore, J.P., Bolognesi, D.P., 1998a. Evidence that anti-
body-mediated neutralization of human immunodeficiency virus type 1
by sera from infected individuals is independent of coreceptor usage. J.
Virol. 72 (3), 1886–1893.
Montefiori, D.C., Reimann, K.A., Wyand, M.S., Manson, K., Lewis,
M.G., Collman, R.G., Sodroski, J.G., Bolognesi, D.P., Letvin, N.L.,
1998b. Neutralizing antibodies in sera from macaques infected with
chimeric simian–human immunodeficiency virus containing the enve-
lope glycoproteins of either a laboratory-adapted variant or a primary
isolate of human immunodeficiency virus type 1. J. Virol. 72 (4),
3427–3431.
Moore, J.P., Doms, R.W., 2003. The entry of entry inhibitors: a fusion
of science and medicine. Proc. Natl. Acad. Sci. U.S.A. 100 (19),
10598–10602.
Moore, J.P., Ho, D.D., 1993. HIV tropism. Nature 361 (6410), 309–310.
Moore, J.P., Ho, D.D., 1995. HIV-1 neutralization: the consequences of
viral adaptation to growth on transformed T cells. AIDS 9 (Suppl. A),
S117–S136.
Moore, J.P., Sodroski, J., 1996. Antibody cross-competition analysis of the
human immunodeficiency virus type 1 gp120 exterior envelope glyco-
protein. J. Virol. 70 (3), 1863–1872.
Moore, J.P., Stevenson, M., 2000. New targets for inhibitors of HIV-1
replication. Nat. Rev., Mol. Cell Biol. 1 (1), 40–49.
Moore, J.P., Sweet, R.W., 1993. The HIV gp120–CD4 interaction: a target
for pharmacological or immunological intervention? Perspect. Drug
Discovery Des. 1, 235–250.
Moore, J.P., McKeating, J.A., Huang, Y.X., Ashkenazi, A., Ho, D.D., 1992.
Virions of primary human immunodeficiency virus type 1 isolates re-
sistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and
glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66
(1), 235–243.
Moore, J.P., Burkly, L.C., Connor, R.I., Cao, Y., Tizard, R., Ho, D.D.,
Fisher, R.A., 1993. Adaptation of two primary human immunodeficien-
cy virus type 1 isolates to growth in transformed T cell lines correlates
with alterations in the responses of their envelope glycoproteins to
soluble CD4. AIDS Res. Hum. Retroviruses 9 (6), 529–539.
Moore, J.P., Cao, Y., Qing, L., Sattentau, Q.J., Pyati, J., Koduri, R., Rob-
inson, J., Barbas III, C.F., Burton, D.R., Ho, D.D., 1995. Primary iso-
lates of human immunodeficiency virus type 1 are relatively resistant to
neutralization by monoclonal antibodies to gp120, and their neutraliza-tion is not predicted by studies with monomeric gp120. J. Virol. 69 (1),
101–109.
Moore, J.P., Kitchen, S., Pugach, P., Zack, J., 2004. The CCR5 and CXCR4
coreceptors—Central to understanding the trail of HIV-1 infection.
AIDS Res. Hum. Retroviruses 20 (1) (in press).
Morikita, T., Maeda, Y., Fujii, S., Matsushita, S., Obaru, K., Takatsuki, K.,
1997. The V1/V2 region of human immunodeficiency virus type 1
modulates the sensitivity to neutralization by soluble CD4 and cellular
tropism. AIDS Res. Hum. Retroviruses 13 (15), 1291–1299.
Moulard, M., Phogat, S.K., Shu, Y., Labrijn, A.F., Xiao, X., Binley, J.M.,
Zhang, M.Y., Sidorov, I.A., Broder, C.C., Robinson, J., Parren, P.W.,
Burton, D.R., Dimitrov, D.S., 2002. Broadly cross-reactive HIV-1-
neutralizing human monoclonal Fab selected for binding to gp120–
CD4–CCR5 complexes. Proc. Natl. Acad. Sci. U.S.A. 99 (10),
6913–6918.
Mulligan, M.J., Ritter Jr., G.D., Chaikin, M.A., Yamshchikov, G.V.,
Kumar, P., Hahn, B.H., Sweet, R.W., Compans, R.W., 1992. Human
immunodeficiency virus type 2 envelope glycoprotein: differential CD4
interactions of soluble gp120 versus the assembled envelope complex.
Virology 187 (1), 233–241.
Ohgimoto, S., Shioda, T., Mori, K., Nakayama, E.E., Hu, H., Nagai, Y.,
1998. Location-specific, unequal contribution of the N glycans in
simian immunodeficiency virus gp120 to viral infectivity and removal
of multiple glycans without disturbing infectivity. J. Virol. 72 (10),
8365–8370.
Olofsson, S., Hansen, J.E., 1998. Host cell glycosylation of viral glycopro-
teins—A battlefield for host defence and viral resistance. Scand. J.
Infect. Dis. 30 (5), 435–440.
Olshevsky, U., Helseth, E., Furman, C., Li, J., Haseltine, W., Sodroski, J.,
1990. Identification of individual human immunodeficiency virus type
1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64
(12), 5701–5707.
Olson, W.C., Rabut, G.E., Nagashima, K.A., Tran, D.N., Anselma, D.J.,
Monard, S.P., Segal, J.P., Thompson, D.A., Kajumo, F., Guo, Y.,
Moore, J.P., Maddon, P.J., Dragic, T., 1999. Differential inhibition of
human immunodeficiency virus type 1 fusion, gp120 binding, and CC-
chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73 (5),
4145–4155.
Pantophlet, R., Ollmann Saphire, E., Poignard, P., Parren, P.W., Wilson,
I.A., Burton, D.R., 2003. Fine mapping of the interaction of neutral-
izing and nonneutralizing monoclonal antibodies with the CD4 bind-
ing site of human immunodeficiency virus type 1 gp120. J. Virol. 77
(1), 642–658.
Park, E.J., Quinnan Jr., G.V., 1999. Both neutralization resistance and high
infectivity phenotypes are caused by mutations of interacting residues in
the human immunodeficiency virus type 1 gp41 leucine zipper and the
gp120 receptor- and coreceptor-binding domains. J. Virol. 73 (7),
5707–5713.
Park, E.J., Gorny, M.K., Zolla-Pazner, S., Quinnan Jr., G.V., 2000. A global
neutralization resistance phenotype of human immunodeficiency virus
type 1 is determined by distinct mechanisms mediating enhanced infec-
tivity and conformational change of the envelope complex. J. Virol. 74
(9), 4183–4191.
Parren, P.W., Moore, J.P., Burton, D.R., Sattentau, Q.J., 1999. The neutral-
izing antibody response to HIV-1: viral evasion and escape from hu-
moral immunity. AIDS 13 (Suppl. A), S137–S162.
Patel, M., Yanagishita, M., Roderiquez, G., Bou-Habib, D.C., Oravecz, T.,
Hascall, V.C., Norcross, M.A., 1993. Cell-surface heparan sulfate pro-
teoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum.
Retroviruses 9 (2), 167–174.
Platt, E.J., Wehrly, K., Kuhmann, S.E., Chesebro, B., Kabat, D., 1998.
Effects of CCR5 and CD4 cell surface concentrations on infections
by macrophagetropic isolates of human immunodeficiency virus type
1. J. Virol. 72 (4), 2855–2864.
Platt, E.J., Kozak, S.L., Kabat, D., 2000. Critical role of enhanced CD4
affinity in laboratory adaptation of human immunodeficiency virus type
1. AIDS Res. Hum. Retroviruses 16 (9), 871–882.
P. Pugach et al. / Virology 321 (2004) 8–2222Pohlmann, S., Doms, R.W., 2002. Evaluation of current approaches to
inhibit HIV entry. Curr. Drug Targets Infect. Disord. 2 (1), 9–16.
Poignard, P., Saphire, E.O., Parren, P.W., Burton, D.R., 2001. gp120: bio-
logic aspects of structural features. Annu. Rev. Immunol. 19, 253–274.
Poignard, P., Moulard, M., Golez, E., Vivona, V., Franti, M., Venturini, S.,
Wang, M., Parren, P.W., Burton, D.R., 2003. Heterogeneity of envelope
molecules expressed on primary human immunodeficiency virus type 1
particles as probed by the binding of neutralizing and nonneutralizing
antibodies. J. Virol. 77 (1), 353–365.
Polonis, V.R., de Souza, M.S., Darden, J.M., Chantakulkij, S., Chuenchitra,
T., Nitayaphan, S., Brown, A.E., Robb, M.L., Birx, D.L., 2003. Human
immunodeficiency virus type 1 primary isolate neutralization resistance
is associated with the syncytium-inducing phenotype and lower CD4
cell counts in subtype CRF01_AE-infected patients. J. Virol. 77 (15),
8570–8576.
Reeves, J.D., Gallo, S.A., Ahmad, N., Miamidian, J.L., Harvey, P.E., Shar-
ron, M., Pohlmann, S., Sfakianos, J.N., Derdeyn, C.A., Blumenthal, R.,
Hunter, E., Doms, R.W., 2002. Sensitivity of HIV-1 to entry inhibitors
correlates with envelope/coreceptor affinity, receptor density, and fusion
kinetics. Proc. Natl. Acad. Sci. U.S.A. 99 (25), 16249–16254.
Reitter, J.N., Means, R.E., Desrosiers, R.C., 1998. A role for carbohydrates
in immune evasion in AIDS. Nat. Med. 4 (6), 679–684.
Reitz Jr., M.S., Wilson, C., Naugle, C., Gallo, R.C., Robert-Guroff, M.,
1988. Generation of a neutralization-resistant variant of HIV-1 is due
to selection for a point mutation in the envelope gene. Cell 54 (1),
57–63.
Richman, D.D., Wrin, T., Little, S.J., Petropoulos, C.J., 2003. Rapid evo-
lution of the neutralizing antibody response to HIV type 1 infection.
Proc. Natl. Acad. Sci. U.S.A. 100 (7), 4144–4149.
Sattentau, Q.J., Arthos, J., Deen, K., Hanna, N., Healey, D., Beverley,
P.C., Sweet, R., Truneh, A., 1989. Structural analysis of the human
immunodeficiency virus-binding domain of CD4. Epitope mapping
with site-directed mutants and anti-idiotypes. J. Exp. Med. 170 (4),
1319–1334.
Shankarappa, R., Margolick, J.B., Gange, S.J., Rodrigo, A.G., Upchurch,
D., Farzadegan, H., Gupta, P., Rinaldo, C.R., Learn, G.H., He, X.,
Huang, X.L., Mullins, J.I., 1999. Consistent viral evolutionary
changes associated with the progression of human immunodeficiency
virus type 1 infection. J. Virol. 73 (12), 10489–10502.
Shattock, R.A., Moore, J.P., 2003. Inhibiting HIV-1 sexual transmission.
Nat. Rev., Microbiol. 1, 25–34.
Si, Z., Cayabyab, M., Sodroski, J., 2001. Envelope glycoprotein determi-
nants of neutralization resistance in a simian–human immunodeficien-
cy virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J. Virol.
75 (9), 4208–4218.
Spenlehauer, C., Kirn, A., Aubertin, A.M., Moog, C., 2001. Antibody-
mediated neutralization of primary human immunodeficiency virus type
1 isolates: investigation of the mechanism of inhibition. J. Virol. 75 (5),
2235–2245.
Stamatatos, L., Wiskerchen, M., Cheng-Mayer, C., 1998. Effect of major
deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1
isolate on viral envelope structure, cell entry, and replication. AIDS
Res. Hum. Retroviruses 14 (13), 1129–1139.
Strizki, J.M., Xu, S., Wagner, N.E., Wojcik, L., Liu, J., Hou, Y., Endres,
M., Palani, A., Shapiro, S., Clader, J.W., Greenlee, W.J., Tagat, J.R.,
McCombie, S., Cox, K., Fawzi, A.B., Chou, C.C., Pugliese-Sivo, C.,
Davies, L., Moreno, M.E., Ho, D.D., Trkola, A., Stoddart, C.A., Moore,
J.P., Reyes, G.R., Baroudy, B.M., 2001. SCH-C (SCH 351125), an orally
bioavailable, small molecule antagonist of the chemokine receptor
CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc.
Natl. Acad. Sci. U.S.A. 98 (22), 12718–12723.
Thali, M., Furman, C., Ho, D.D., Robinson, J., Tilley, S., Pinter, A.,
Sodroski, J., 1992. Discontinuous, conserved neutralization epitopesoverlapping the CD4-binding region of human immunodeficiency virus
type 1 gp120 envelope glycoprotein. J. Virol. 66 (9), 5635–5641.
Tokunaga, K., Greenberg, M.L., Morse, M.A., Cumming, R.I., Lyerly, H.K.,
Cullen, B.R., 2001. Molecular basis for cell tropism of CXCR4-depen-
dent human immunodeficiency virus type 1 isolates. J. Virol. 75 (15),
6776–6785.
Trkola, A., Pomales, A.B., Yuan, H., Korber, B., Maddon, P.J., Allaway,
G.P., Katinger, H., Barbas III, C.F., Burton, D.R., Ho, D.D., 1995.
Cross-clade neutralization of primary isolates of human immunodefi-
ciency virus type 1 by human monoclonal antibodies and tetrameric
CD4-IgG. J. Virol. 69 (11), 6609–6617.
Trkola, A., Ketas, T., Kewalramani, V.N., Endorf, F., Binley, J.M.,
Katinger, H., Robinson, J., Littman, D.R., Moore, J.P., 1998a. Neutral-
ization sensitivity of human immunodeficiency virus type 1 primary
isolates to antibodies and CD4-based reagents is independent of core-
ceptor usage. J. Virol. 72 (3), 1876–1885.
Trkola, A., Paxton, W.A., Monard, S.P., Hoxie, J.A., Siani, M.A., Thomp-
son, D.A., Wu, L., Mackay, C.R., Horuk, R., Moore, J.P., 1998b.
Genetic subtype-independent inhibition of human immunodeficiency
virus type 1 replication by CC and CXC chemokines. J. Virol. 72 (1),
396–404.
Trkola, A., Kuhmann, S.E., Strizki, J.M., Maxwell, E., Ketas, T., Morgan,
T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S.,
Clader, J.W., McCombie, S., Reyes, G.R., Baroudy, B.M., Moore, J.P.,
2002. HIV-1 escape from a small molecule, CCR5-specific entry inhib-
itor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U.S.A. 99 (1),
395–400.
Turner, S., Tizard, R., DeMarinis, J., Pepinsky, R.B., Zullo, J., Schooley,
R., Fisher, R., 1992. Resistance of primary isolates of human immuno-
deficiency virus type 1 to neutralization by soluble CD4 is not due to
lower affinity with the viral envelope glycoprotein gp120. Proc. Natl.
Acad. Sci. U.S.A. 89 (4), 1335–1339.
Tuttle, D.L., Harrison, J.K., Anders, C., Sleasman, J.W., Goodenow, M.M.,
1998. Expression of CCR5 increases during monocyte differentiation
and directly mediates macrophage susceptibility to infection by human
immunodeficiency virus type 1. J. Virol. 72 (6), 4962–4969.
Ugolini, S., Mondor, I., Parren, P.W., Burton, D.R., Tilley, S.A., Klasse,
P.J., Sattentau, Q.J., 1997. Inhibition of virus attachment to CD4+
target cells is a major mechanism of T cell line-adapted HIV-1 neu-
tralization. J. Exp. Med. 186 (8), 1287–1298.
Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-
Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L.,
Nowak, M.A., Hahn, B.H., Kwong, P.D., Shaw, G.M., 2003. Antibody
neutralization and escape by HIV-1. Nature 422 (6929), 307–312.
Willey, R.L., Martin, M.A., Peden, K.W., 1994. Increase in soluble CD4
binding to and CD4-induced dissociation of gp120 from virions corre-
lates with infectivity of human immunodeficiency virus type 1. J. Virol.
68 (2), 1029–1039.
Wrin, T., Loh, T.P., Vennari, J.C., Schuitemaker, H., Nunberg, J.H., 1995.
Adaptation to persistent growth in the H9 cell line renders a primary
isolate of human immunodeficiency virus type 1 sensitive to neutrali-
zation by vaccine sera. J. Virol. 69 (1), 39–48.
Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J., Sodroski, J.,
1995. Involvement of the V1/V2 variable loop structure in the exposure
of human immunodeficiency virus type 1 gp120 epitopes induced by
receptor binding. J. Virol. 69 (9), 5723–5733.
Wyatt, R., Kwong, P.D., Desjardins, E., Sweet, R.W., Robinson, J., Hen-
drickson, W.A., Sodroski, J.G., 1998. The antigenic structure of the
HIV gp120 envelope glycoprotein. Nature 393 (6686), 705–711.
Ye, Y., Si, Z.H., Moore, J.P., Sodroski, J., 2000. Association of structural
changes in the V2 and V3 loops of the gp120 envelope glycoprotein
with acquisition of neutralization resistance in a simian–human immu-
nodeficiency virus passaged in vivo. J. Virol. 74 (24), 11955–11962.
